Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008

Tuesday, February 12, 2008 General News J E 4
COPENHAGEN, Denmark, Feb. 11 Santaris Pharma, the Danishbiopharmaceutical company developing LNA based RNA medicines, announced todaythat Keith McCullagh, President and Chief Executive Officer, will bepresenting an overview of the company and its goals for 2008 at theBiotechnology Industry Organisation's 10th Annual CEO & Investor Conference inNew York, today, Monday February 11th at 12:30 pm, US Eastern Standard Time(18:30 Central European Time). The conference is being held at the WaldorfAstoria Hotel, New York City from February 11th-13th, 2008.

A live webcast of the Santaris Pharma presentation may be accessed fromthe news section of the company's website,, where itwill also be archived and available after the presentation.

About Santaris Pharma

Santaris Pharma is a Danish based clinical-stage biopharmaceuticalcompany. The company was formed in 2003 and currently employs around 100people. Santaris Pharma has the exclusive rights to LNA technology, a 3rdgeneration antisense chemistry used to develop new classes of RNA medicines,called RNA Antagonists and microRNA antagonists. Santaris Pharma's RNAAntagonists are targeted against tissue specific mRNAs associated with cancer,metabolic disorders and viral disease. In May 2006 Santaris Pharma completed aEuro 40m second round of equity financing and in December 2007 the Companycompleted a Euro 20m third round of equity financing. Santaris Pharma has aglobal partnership with Enzon Pharmaceuticals of New Jersey to co-develop andcommercialise a series of Santaris Pharma RNA Antagonists for improving thetreatment of cancer. GlaxoSmithKline has options to up to four Santaris Pharmadrug candidates targeted against viral disease.For further information please contact Randi Krogsgaard, Director Corporate Communications Direct phone: +45 45179879 Cell: +45 20488384 E-mail:

SOURCE Santaris Pharma


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Update on Progression of Phosphagenics and Nestle ...
Lumenis(R) Seeks Shareholder Approval of Proposed ...